Anti-idiotype sera raised against surface immunoglobulin of human neoplastic lymphocytes
- PMID: 62018
- PMCID: PMC2190432
- DOI: 10.1084/jem.144.4.960
Anti-idiotype sera raised against surface immunoglobulin of human neoplastic lymphocytes
Abstract
The idiotypic determinants of surface immunoglobulins on B-cell lymphomas and lymphocytic leukemias represent tumor-specific antigens, individually unique for each tumor. As such they have both diagnostic and therapeutic potential, particularly for those neoplasms with no serum monoclonal immunoglobulin arising from synthesis of the protein for export. We describe the raising in animals of anti-idiotype sera directed against two examples of a nonexporting neoplasm, human chronic lymphocytic leukemia. The procedure involves exposing the cells to papain so as to remove the Fab fragments (containing the idiotypic determinants) from the surface immunoglobulin, recovering the Fab on cellulose immunosorbent particles, and immunizing animals with the immunosorbent-Fab complex.
Similar articles
-
Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: a therapeutic target.Fed Proc. 1977 Aug;36(9):2268-71. Fed Proc. 1977. PMID: 69552 No abstract available.
-
Extracellular idiotypic immunoglobulin arising from human leukemic B lymphocytes.J Exp Med. 1980 Dec 1;152(6):1484-96. doi: 10.1084/jem.152.6.1484. J Exp Med. 1980. PMID: 6969771 Free PMC article.
-
Same idiotype of B-lymphocyte membrane IgD and IgM. Formal evidence for monoclonality of chronic lymphocytic leukemia cells.Scand J Immunol. 1974;3(6):841-6. doi: 10.1111/j.1365-3083.1974.tb01321.x. Scand J Immunol. 1974. PMID: 4142108 No abstract available.
-
BCL1, a murine model for chronic lymphocytic leukemia: use of the surface immunoglobulin idiotype for the detection and treatment of tumor.Immunol Rev. 1979;48:81-106. doi: 10.1111/j.1600-065x.1979.tb00299.x. Immunol Rev. 1979. PMID: 94899 Review. No abstract available.
-
Expression and dynamics of membrane immunoglobulins.Pharmacol Rev. 1982 Mar;34(1):65-72. Pharmacol Rev. 1982. PMID: 6803260 Review. No abstract available.
Cited by
-
Integration of the B-Cell Receptor Antigen Neurabin-I/SAMD14 Into an Antibody Format as New Therapeutic Approach for the Treatment of Primary CNS Lymphoma.Front Oncol. 2020 Nov 12;10:580364. doi: 10.3389/fonc.2020.580364. eCollection 2020. Front Oncol. 2020. PMID: 33282736 Free PMC article.
-
Antigenic modulation of lymphocytic surface immunoglobulin yielding resistance to complement-mediated lysis. I. Characterization with syngeneic and xenogeneic complements.Immunology. 1981 Jan;42(1):7-12. Immunology. 1981. PMID: 6970174 Free PMC article.
-
The B-cell Receptor Autoantigen LRPAP1 Can Replace Variable Antibody Regions to Target Mantle Cell Lymphoma Cells.Hemasphere. 2021 Jul 13;5(8):e620. doi: 10.1097/HS9.0000000000000620. eCollection 2021 Aug. Hemasphere. 2021. PMID: 34263144 Free PMC article.
-
Rescue of immunoglobulin secretion from human neoplastic lymphoid cells by somatic cell hybridization.Proc Natl Acad Sci U S A. 1978 May;75(5):2411-5. doi: 10.1073/pnas.75.5.2411. Proc Natl Acad Sci U S A. 1978. PMID: 97669 Free PMC article.
-
Lymphoblastoid cell lines from patients with chronic lymphocytic leukemia: identification of tumor origin by idiotypic analysis.Proc Natl Acad Sci U S A. 1978 Nov;75(11):5706-10. doi: 10.1073/pnas.75.11.5706. Proc Natl Acad Sci U S A. 1978. PMID: 82971 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
